ALSO NOTED: Novartis sued over withdrawn child cold meds; Teva to expand, hire in Czech Republic;

In what could be a harbinger of more lawsuits over the OTC cold meds for children that FDA warned against and companies withdrew last fall, a California mother sued Novartis over its Triaminic cough-and-cold products. Report

Teva Pharmaceuticals' Ivax unit plans to spend $60.7 million to expand its plant in the Czech Republic, planning to add 400 workers there and amp up production threefold. Report

Sciele Pharma announced it would buy several products from Verus Pharmaceuticals for $29 million, including the emergency allergy shot Twinject. Report

Isis Pharmaceuticals reported a fourth-quarter loss of $7 million on revenues of $24.7 million, falling short of analyst estimates. Report

For the first time, federal authorities are conceding a link between vaccines and autistic symptoms--just not the link activists thought. Report

The venture capital group Perseus has pumped $10 million dollars into NanoBio, bringing its total investment in the University of Michigan spin-off to $30 million. Report

Amgen got some much-needed good news yesterday after an FDA panel endorsed the approval of Nplate, its drug for a rare blood disorder. Report

Genentech CEO Arthur Levinson (photo) scooped up close to $14 million in compensation last year, even as its stock price slid in the face of slowing cancer therapy revenues. Report

Most popular this week: Pfizer's Kindler can't quash mega-deal talk. Report

And Finally... Could public funding make drug R&D more efficient? Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.